Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice

Idiopathic pulmonary fibrosis (IPF) patients have a high risk of developing lung cancer, with few treatment options available. Pirfenidone, an antifibrotic agent approved for the treatment of IPF, has been demonstrated to suppress the TGFβ signaling and modulate the expression of immune-related gene...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncoimmunology
Hlavní autoři: Qin, Wan, Zou, Jun, Huang, Yongbiao, Liu, Chaofan, Kang, Yalin, Han, Hu, Tang, Yang, Li, Long, Liu, Bo, Zhao, Weiheng, Yuan, Xianglin
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2020
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7781712/
https://ncbi.nlm.nih.gov/pubmed/33457101
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1824631
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky